Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transvamix for chronic pain in epidermolysis bullosa: randomized, placebo-controlled crossover trial
2021-000103-20Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Transvamix in epidermolysis bullosa (EB) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Pain unpleasantness reduction (30% and 50%). Started Jul 2021; status: active.
02
Drugs
Transvamix
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2021-000103-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000103-20.